Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Multiple myeloma is a cancer of plasma cells.
• High tumor burden and specific clinical indicators (low hemoglobin, high calcium) denote advanced disease.
• Effective treatment options for previously untreated patients with advanced multiple myeloma are crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of thalidomide-dexamethasone combination therapy.
• To assess treatment outcomes in a cohort of previously untreated multiple myeloma patients with high tumor mass.

Main Methods:

• A consecutive series of 26 previously untreated multiple myeloma patients with high tumor mass were treated with thalidomide-dexamethasone.
• Patient eligibility included low hemoglobin or elevated serum calcium levels.
• Outcomes assessed included response rate, early death, survival, remission duration, and adverse events.

Main Results:

• The overall response rate was 73%.
• The frequency of early death within 3 months was 5%.
• Projected median survival was 30 months, and projected median remission duration was 25 months.
• No grade 3 or 4 neutropenia or thrombocytopenia occurred, with serious infections in only 12% of patients.

Conclusions:

• Thalidomide-dexamethasone is a valuable treatment for advanced multiple myeloma.
• The combination therapy offers a high response rate and acceptable survival.
• The treatment is associated with a low frequency of serious complications, making it a viable option for high-risk patients.